While STAT6 immunohistochemistry strongly supported the diagnosis of SFT, molecular confirmation of the NAB2-STAT6 fusion could have further validated the diagnosis and provided additional insight into potential therapeutic targets. The gene discussed is STAT6; the disease is solitary fibrous tumor.